Member Info for Hulver

Slide 9:

CBR- Chimeric Bait Receptor and BME – Bait Macrophage Engager Design Concepts I

What is CBR?

• CBRs program the immune cells that are responsible for innate immunity to precisely target and eliminate a range of pathogenic viruses and cells.

• CBRs contain a portion of the protein to which a pathogenic virus or cell binds, acting as bait for the virus or cell and allowing immune cells to destroy them.

• CBRs are used in the context of cell therapy treatment.

What is BME?

• BMEs redirect the immune cells that are responsible for innate immunity to precisely target and eliminate a range of pathogenic viruses and cells.

• BMEs contain a portion of the protein to which a pathogenic virus or cell binds, acting as bait for the virus or cell and allowing immune cells to destroy them. BMEs also contain a ligand for an immune cell receptor.

• BMEs enable the generation of cell-independent constructs that will be used as off-the-shelf drugs for the treatment of viral infections as well as certain types of cancer.

Slide 10:

{A 'cartoon' illustrating CBR mechanism and BME mechanism for eliminating SARS-CoV-2.}

Slide 7:

Unmet Need – Brain Cancers

Threats

Brain cancers including gliomas.

Solution

We have developed a fundamentally new cell therapy – Chimeric Bait Receptor – that will be used in combination with programed haematopoietic stem cells (HSC) to cross blood brain barrier (BBB) to eliminate brain tumors.

Goals

Develop reliable treatment of malignant brain tumors such as glioblastoma multiforme (GBM).

Slide 8:

Why Do We Need New Solutions

Shortcomings of Existing Methods of Combating Viral Infections

• Vaccines – sensitive to emerging mutations of the virus; designed to fight only one viral species.

• Anti-Viral Drugs – sensitive to emerging mutations of the virus; difficult and slow to develop; designed to fight only one viral species.

• Antibodies – sensitive to emerging mutations of the virus; designed to fight only one viral species.

Advantages of CBR/BME

• CBRs/BMEs are insensitive to emerging mutations of the virus

• CBRs/BMEs are assembled from parts of naturally occurring cellular receptors/ligands that are responsible for the function of immune cells and endow the host’s immune system with the ability to destroy invading pathogens.

• CBRs/BMEs are modular synthetic receptors/biologics that can be rapidly reconfigured to attack a multitude of viruses often belonging to different viral families. They can also be used to fight bacterial infections and certain types of cancer.

• CBRs/BMEs can be configured to have long shelf life and easy deployment/administration at ambient temperatures.

Slide 4:

Bait Biotechnology is developing:

1. Product type: Antivirals. Brain cancers treatments.

2. Mechanism of action: BAIT based programing or redirection of macrophage using novel synthetic proteins.

3. Significant Advantages:

a. Single therapeutic targeting multiple viral infections.

b. Long shelf life at ambient temperature.

c. Easy deployment/administration at ambient temperature.

d. Cross Blood Brain Barrier to target brain tumors.

Slide 5:

Unmet Need – Viral Infections

Threats

- Global pandemics

- Biological warfare

Solution

We have developed a fundamentally new cell therapy – Chimeric Bait Receptor – and its derivatives, including Bait Macrophage Engagers (BME) - that will be used to prevent and/or combat infection by any known or emerging virus.

Goals

- Prevent future global pandemics

- Render virus-based bio-threats ineffective

- Provide American warfighters with an overwhelming advantage over adversaries that use biological warfare

Slide 6:

Antivirals and Vaccines

{Several bar charts showing Global market size, and expected US$ CAGR in treatment sales over what appears to be next ten years, for the following.}

Global Market Size for Antivirals

Global Market Size for Dengue treatments

Global Market Size for Influenza treatments

Global Market Size for Covid-19 treatments

Global Market Size for Ebola treatments

Global Market Size for Marburg treatments

In what follows I will post the information given on the slides as far as it can be ascertained:

Slide 1:

BAIT Biotechnology

Outsmart – Prevent - Cure

Immune Cell Programming

Chimeric Bait Receptor (CBR) Platform

Bait Macrophage Engager (BME) Platform

September 2023

Slide 2:

Company Overview

• Hemogenyx Pharmaceuticals developed a novel platform for the development of radically new treatments of existing and emerging viral infections and certain types of cancer. The platform is being spun out as a subsidiary Bait Biotechnology (PCT/US2023/063514).

• Hemogenyx Pharmaceuticals and Bait Biotechnology are in West Harlem of Manhattan, New York City.

Bait Biotechnology enjoys:

1. Access to the R&D infrastructure of Hemogenyx Pharmaceuticals.

2. Access to the manufacturing infrastructure of Hemogenyx Pharmaceuticals

3. Access to a network of Advisors, Board of Directors, business and fundraising experience as well as talent of its parent company.

Slide 3:

Experienced Team

Vladislav Sandler, CEO

Andrew Wright, Financial Controller

Alexis Sandler, Non-Executive Director

Sir Marc Feldman, Chairman (Lasker Award)

Peter Redmond, Non-Executive Director

Koen van Besien, Clinical Adviser

Michael Sheppard, Scientific Adviser (Lasker Award)

Alan Walts (Board Adviser)

In September 2023 Vlad took part in the RESI Boston Innovators Pitch Challenge

(RESI - Redefining Early Stage Investments)

A video of the pitch was circulated later online - otherwise, HEMO's participation in this was not communicated to investors.

Primarily the purpose seems to have been the introduction of the company's CBR platform and its proposed future development, through a subsidiary BAIT Biotechnology, to an investor audience.

At the very end of the presentation a representative of Prevail Therapeutics interjects to advise that they are 'a committed investor' in Hemogenyx and for anyone interested in joining them to come and talk them afterwards. Thinking about it now - Prevail may have arranged for Vlad to participate in this, as Prevail may be a regular attendee at such events.

Here is the link to the youtube video again:

https://www.youtube.com/watch?v=X8tYUMq1Oo0

PT, vague recollection is that in one of the Q&A's, possibly at the AGM, another investor asked about HEMO-SAFE-CAR-T and the response was along the lines that, although they had developed a safety switch (to counter potential cytokine storm), they have not used it in HEMO-CAR-T as third generation CAR-T (and I think this may be in general now) does not show any significant signs of CRS, and are considered safe enough, based on pre-clinical studies - or words to that effect. I presume that this decision would have come as a result of the development and tests under the collaboration with UPenn.

JHFH - my thoughts too - today's RNS makes CDX eminently more partnerable, with someone to help take it into IND and clinical trial.

HEMO CAR-T - FDA decision pending.

Meanwhile CBR is being spun out into BAIT Biotechnology (a subsidiary) at some point 'coming soon' with new investment - to take that forward against viruses and some brain cancers. Per the September slides (Vlad used at the RESI Boston conference) - CBRs/BMEs for several families of viruses are 'in works', 'designed' - the technology is ready for translational science to develop and test products.

Here's the link to the RESI Boston Innovator's Pitch as it's been long since buried:

https://www.youtube.com/watch?v=X8tYUMq1Oo0

I may post some more detail from the slides over the weekend, when the quantity of posts has died down.

HH, my thoughts too, I'd hope the next raise is circa £20m and the next stage of each product CAR-T, CDX and CBR is funded.

Hopefully Dr Alan Walts has been doing his bit to prepare/engage PIPE funding round investors over the last two years as well as Prevail. And as Prevail were taking a 'still pre-clinical' placing risk there is reason to consider that their 6p minimum funding level injection was at a discount to the PIPE price.

Then a strategy of buying at each past dilution to maintain 20% more shares than the percentage ownership you ultimately want to hold (after dilution) may be well rewarded.

EFM, thank you for posting - I had never ever heard that song, what relevant lyrics.

Under the radar and an enigma, very much like HEMO.

and hopefully

'Everything's falling into place'

First day of admission & trading - 5th October 2017 - born on a Thursday

Thursday's child..........

GLA

Apologies if already posted. Action Stations - CBR Team?

https://www.linkedin.com/posts/vladislavsandler_no-virus-will-escape-activity-7154309222757728256-nixV?

Michael Haugbro, Ronen ben Jehuda and Vladislav Sandler

"nothing is certain except death and taxes"

but wait, for AML sufferers let's hope that soon becomes just "taxes" and that they have many more years of health ahead of them.

A life saving company!

For those that were considering company valuations (tweeted by Vlad a while back):

https://twitter.com/vmsandler/status/1630290333148884992/photo/1

Many years - I hope. This is just the start of the HEMO Fountain.

Great team of young scientists, new facilities, top life sciences location, latest equipment, proven advisors and mentors - and, we are told, potential for solutions to a range of illnesses through CAR-T, CDX and CBR, and I expect that there is much more that we do not know about.

PIPE Funding Round

When the Prevail Partners investment was first announced on a Prevail news item they stated that they had invested as part of Hemogenyx's PIPE funding round (I remember having to look up what PIPE stood for).

Here's some literature on what that might mean. After reading the initial summary pages scroll down to the UK section.

https://www.bakermckenzie.com/-/media/files/insight/publications/2020/06/global-private-investment-in-public-equity-guide-050620.pdf

I think this is already lined up and led by Prevail, since, as Vlad has confirmed in the penultimate RNS, there is a disconnect between the market price and the value. What will the price be and how much will be raised?

Those 3% of investor positions that are short will need to wriggle out of them too.

We know also that Prevail were touting for investment in Hemo at the 'undisclosed' Bait Biotechnology presentation; so I consider this funding round will not just be for CAR-T clinical trial, but at least for CBR as well.

Moorscloud, I found the below in relation to a funding round led by Prevail for PolyPhotonix. This would suggest that the funding is lined up (and probably was ready prior to the unexpected clinical hold) but also suggests that it will only be advanced on the commencement of HEMO CAR-T clinical trial. This ties in with a HEMO RNS which indicated a further funding round would happen at the commencement of clinical trial. As the commencement didn't happen as planned, it seems that a further raise was needed through the previous channels. But it seems that everything could be ready to go, on lifting of CH. Was the amount advanced by Prevail in September, therefore a partial funding attempt to get HEMO through to clinical hold lift?

"Prevail Partners, an affiliate of Prevail CInfoWorks, has led a USD10 million Series A funding round in PolyPhotonix Limited, a developer of a noninvasive treatment for diabetic retinopathy.

Prevail Partners, an affiliate of Prevail CInfoWorks, has led a USD10 million Series A funding round in PolyPhotonix Limited, a developer of a noninvasive treatment for diabetic retinopathy.

The investment will be made on the commencement of an FDA regulated human clinical trial of PolyPhotonix’s Noctura 400 Sleep Mask.

Prevail InfoWorks Inc, is a global company based in Philadelphia in the United States, providing biotech, pharmaceutical, medical device and diagnostics companies with the most innovative and complete technology and service solutions for their clinical development. The deal will leverage Prevail InfoWorks’ capabilities and technological expertise for achieving the highest quality data in the shortest possible time to expedite the clinical trial process."

https://www.privateequitywire.co.uk/polyphotonix-secures-usd10m-series-round-led-prevail-partners/

The question is, how much funding will be brought in (assuming CH gets clearance) and at what price.

Completion of PIPE funding round (the extra raise in November has afforded the opportunity for further investment to be gained, and hopefully that was a particular targeted objective whilst attending the conference).

So the question is how much is being raised for the next stage of development - the BAIT Biotechnology spin-out, the CAR-T clinical trial and the CDX IND and will it also be at 6p.

From the RNS issued just 28th November:

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,

commented:

"The markets have at last started to recognise the significant recent progress

that the Company has made in the development of both HEMO-CAR-T and CBR

platform. Today's Placing will enable the Company to progress with its

ambitious schedule to move forward to clinical trials of this exciting

potential treatment for AML as well as to further expand the use our CBR

platform for the treatment of solid tumours."